Compare AVNT & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNT | ARQT |
|---|---|---|
| Founded | 1927 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2000 | 2020 |
| Metric | AVNT | ARQT |
|---|---|---|
| Price | $43.01 | $26.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $53.13 | $40.38 |
| AVG Volume (30 Days) | 651.6K | ★ 2.0M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 1.77 | 0.09 |
| Revenue | ★ $3,835,500,000.00 | $376,072,000.00 |
| Revenue This Year | $6.78 | $44.19 |
| Revenue Next Year | $4.02 | $29.31 |
| P/E Ratio | ★ $24.48 | $302.33 |
| Revenue Growth | 1.71 | ★ 91.34 |
| 52 Week Low | $28.50 | $19.30 |
| 52 Week High | $49.08 | $34.80 |
| Indicator | AVNT | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 41.77 |
| Support Level | $35.57 | $25.08 |
| Resistance Level | $46.11 | $28.67 |
| Average True Range (ATR) | 1.42 | 1.59 |
| MACD | -0.34 | -0.35 |
| Stochastic Oscillator | 2.67 | 12.64 |
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two reportable segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The Color, Additives, and Inks segment and the distribution segment generate maximum revenue. Geographically, the company generates maximum revenue from the United States and Canada, followed by EMEA, Asia, and Latin America.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.